The effect of desmopressin in reducing bleeding after cardiac surgery

The effect of desmopressin in reducing bleeding after cardiac surgery in patients receiving antiplatelet drugs in comparison with placebo

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013092114728N1

Enrollment

Registered

2014-03-19

Start date

2014-02-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding after cardiac surgery. Other specified coagulation defects

Interventions

Intervention 1: Administration of DDAVP nasal spray 2 puffs before admission to ICU and 6 hours later. Intervention 2: Administration of saline nasal spray 2 puffs before admission to ICU and 6 hours

Treatment - Drugs

Placebo

Administration of DDAVP nasal spray 2 puffs before admission to ICU and 6 hours later

Administration of saline nasal spray 2 puffs before admission to ICU and 6 hours later in control group

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: CABG surgery under CPB, Age over 18 years, Anti-platelet drugs for one week before surgery Exclusion Criteria: Heart surgery (other than surgery to control bleeding), coagulation disorders, anticoagulation before surgery, patient dissatisfaction, sensitivity to DDAVP, kidney disease, liver disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Amount of Bleeding. Timepoint: Every 6 hours. Method of measurement: ML.	—

Secondary

Measure	Time frame
Duration of ICU stay. Timepoint: After Intervention. Method of measurement: Hour.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Kamran Shadvar

Tabriz University of Medical Scieces

shadvark@tbzmed.ac.ir+98 41 1335 7767

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026